Gyldmark M - Search Results

1

Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza: illustration for the Netherlands.

Postma MJ, Novak A, Scheijbeler HW, Gyldmark M, van Genugten ML, Wilschut JC. Postma MJ, et al. Among authors: gyldmark m. Pharmacoeconomics. 2007;25(6):497-509. doi: 10.2165/00019053-200725060-00005. Pharmacoeconomics. 2007. PMID: 17523754

2

Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK.

Sander B, Hayden FG, Gyldmark M, Garrison LP Jr. Sander B, et al. Among authors: gyldmark m. Pharmacoeconomics. 2006;24(4):373-86. doi: 10.2165/00019053-200624040-00007. Pharmacoeconomics. 2006. PMID: 16605283

3

Economic impact of the AIDS epidemic in the European Community: towards multinational scenarios on hospital care and costs.

Postma MJ, Leidl R, Downs AM, Rovira J, Tolley K, Gyldmark M, Jager JC. Postma MJ, et al. Among authors: gyldmark m. AIDS. 1993 Apr;7(4):541-53. doi: 10.1097/00002030-199304000-00014. AIDS. 1993. PMID: 8507419 Review.

4

Pharmacoeconomic assessment of oseltamivir in treating influenza--the case of otherwise healthy Danish adolescents and adults.

Vindt Holm M, Gyldmark M, Holme Hansen E. Vindt Holm M, et al. Among authors: gyldmark m. Pharm World Sci. 2004 Dec;26(6):339-45. doi: 10.1007/s11096-004-0559-2. Pharm World Sci. 2004. PMID: 15683104

5

Influenza treatment with neuraminidase inhibitors: cost-effectiveness and cost-utility in healthy adults in the United Kingdom.

Sander B, Gyldmark M, Hayden FG, Morris J, Mueller E, Bergemann R. Sander B, et al. Among authors: gyldmark m. Eur J Health Econ. 2005 Sep;6(3):244-52. doi: 10.1007/s10198-005-0297-y. Eur J Health Econ. 2005. PMID: 15875227 Free PMC article.

6

Impact of influenza treatment with oseltamivir on health, sleep and daily activities of otherwise healthy adults and adolescents.

Bettis R, Iacuzio D, Jung T, Fuchs R, Aultman R, Gyldmark M. Bettis R, et al. Among authors: gyldmark m. Clin Drug Investig. 2006;26(6):329-40. doi: 10.2165/00044011-200626060-00004. Clin Drug Investig. 2006. PMID: 17163267

7

Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom.

Lewis G, Peake M, Aultman R, Gyldmark M, Morlotti L, Creeden J, de la Orden M. Lewis G, et al. Among authors: gyldmark m. J Int Med Res. 2010 Jan-Feb;38(1):9-21. doi: 10.1177/147323001003800102. J Int Med Res. 2010. PMID: 20233509 Free article.

8

Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities.

Van Vlaenderen I, Canon JL, Cocquyt V, Jerusalem G, Machiels JP, Neven P, Nechelput M, Delabaye I, Gyldmark M, Annemans L. Van Vlaenderen I, et al. Among authors: gyldmark m. Acta Clin Belg. 2009 Mar-Apr;64(2):100-12. doi: 10.1179/acb.2009.019. Acta Clin Belg. 2009. PMID: 19432022 Review.

9

Effect of influenza treatment with oseltamivir on health outcome and costs in otherwise healthy children.

Reisinger K, Greene G, Aultman R, Sander B, Gyldmark M. Reisinger K, et al. Among authors: gyldmark m. Clin Drug Investig. 2004;24(7):395-407. doi: 10.2165/00044011-200424070-00003. Clin Drug Investig. 2004. PMID: 17516726

10

The treatment and care costs of people with HIV infection or AIDS: development of a standardised cost framework for Europe.

Tolley K, Gyldmark M. Tolley K, et al. Among authors: gyldmark m. Health Policy. 1993 Apr;24(1):55-70. doi: 10.1016/0168-8510(93)90088-7. Health Policy. 1993. PMID: 10125812 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21 results

Search Page

Filters